Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Charles Lackey

Gastroenterology Norman, OK Medical Doctor

NPI 1285625640 CMS profile 194465

1515 N Porter Ave, Suite 200, Norman, OK 73071

Open in the dashboard

General payments

$9,158

631 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Charles Lackey of Norman, OK is reported in the CMS Open Payments database as having received $9,158 across 631 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $17 1
2023 General $249 15
2022 General $2,640 178
2021 General $2,607 187
2020 General $1,713 117
2019 General $1,932 133

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Lackey
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Charles Lackey were reported at $0. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Charles Lackey Gastroenterology median Middle half National median
2019 $1,932 $417 $126–$1,100 $163
2020 $1,713 $224 $74–$624 $114
2021 $2,607 $352 $106–$1,054 $132
2022 $2,640 $448 $129–$1,270 $149
2023 $249 $533 $150–$1,390 $160
2024 $17 $605 $160–$1,606 $164
2025 $0 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AbbVie, Inc. $2,083 136 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,789 137 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $1,367 105 payments
  4. Janssen Biotech, Inc. $768 55 payments
  5. Daiichi Sankyo Inc. $541 36 payments
  6. Ironwood Pharmaceuticals, Inc $437 31 payments
  7. Gilead Sciences, Inc. $363 30 payments
  8. Intercept Pharmaceuticals, Inc. $313 18 payments
  9. QOL Medical, LLC $168 11 payments
  10. Braintree Laboratories, Inc. $153 10 payments
  11. Other $1,176 62 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $9,137 629 payments
  2. Consulting Fee $15 1 payment
  3. Education $6 1 payment
Products named General payments · program years 2019–2024
  1. XIFAXAN $1,673 130 payments
  2. STELARA $872 55 payments
  3. ENTYVIO $729 60 payments
  4. TRULANCE Gastroenterology $649 53 payments
  5. HUMIRA $587 35 payments
  6. CREON $567 47 payments
  7. LINZESS Gastroenterology $526 44 payments
  8. Linzess Gi $374 27 payments
  9. TRULANCE Gastroenterology $348 24 payments
  10. INJECTAFER $310 23 payments
  11. Other $4,267 273 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

631 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record